Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
US9550821B2 · kind B2 · utility
0Cited by
11References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 14, 2012 |
| Grant date | Jan 24, 2017 |
| Priority date | — |
| Expiry date | Aug 10, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction in ghrelin/unacylated ghrelin ratio is beneficial to the subject. Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio as biomarkers for determining a subject's likelihood of responding to and/or benefiting from administration of unacylated ghrelin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.